Market Cap N/A
Revenue (ttm) 46.92M
Net Income (ttm) -38.10M
EPS (ttm) N/A
PE Ratio N/A
Forward PE 0.00
Profit Margin -81.20%
Debt to Equity Ratio N/A
Volume 775,700
Avg Vol 145,364
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 80%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclero...

Industry: Biotechnology
Sector: Healthcare
Phone: 778 731 1711
Website: nervgen.com
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
shopno
shopno Aug. 14 at 5:41 AM
$NGEN appreciate the timelines compilation.. This timeline is even slower than my independent projection.. so 2029 H2 is the timeline to get nvg-291 in general regulatory process! My goodness! What a horrible management to take 15+ months from P1/2 topline to P3 initiation — that’s even for a p3 only with target 150 enrollment. Bag holders should be glad stock is not trading in pennies. Dead money for next few quarters. Down only -72% from 52w peak even after gait data.
0 · Reply
Skaped
Skaped Aug. 14 at 3:49 AM
$NGEN Once again a few sneaky changes have been made on the website. 1) Page 31 of presentation has been updated: SEPTEMBER 2026: RESTORE site activation and participant screening FALL 2026: Formal announcement of additional clinical indications for NVG-291 with biological rationale 2H 2027: Completion of enrollment in Phase 3 RESTORE study 1H 2028: Topline Data from Phase 3 RESTORE study 2H 2028: New Drug Application submission to FDA in chronic spinal cord injury 2) NervGen is tossing away the term "Chronic Tetraplegia" and has changed nearly everything to "Chronic Spinal Cord Injury". This is more directly advertising they are aiming for commercialization for all of it. Even their presentation has changed the wording from "Mid-2028 New Drug Application submission to FDA in chronic tetraplegia" to "2H 2028 New Drug Application submission to FDA in chronic spinal cord injury"
0 · Reply
Tarquinjones
Tarquinjones Aug. 14 at 1:45 AM
$NGEN Most meaningful part of today’s release Key secondary endpoints include the Patient and Clinician Global Impression of Change, the Spinal Cord Independence Measure Version III, and the Modified Ashworth Scale for spasticity. A blinded qualitative interview will also assess participants’ lived experience during RESTORE and contextualize clinically meaningful change.
0 · Reply
shopno
shopno Aug. 14 at 12:29 AM
$NGEN As have predicted lately, p3 already got delayed from mid-2026 (Q2) to late Q3. In no world, this incompetent management without any prior experience of launching any blockbuster drug, would keep pushing down p3 completion timeline. I don’t see NGEN can finish p3 enrollment by Q2 2027, so that dosing and data collections could all be done by Q4 2027. We may have a better idea after Q4 earning release, like how many patients got enrolled throughout Q4 quarter. Of course management utterly lacks in professional communication, like how poorly they released the gait analysis data, so they could just mention enrollment ongoing without revealing extract figure . With all that I have limited hope nvg-291 will reach patients before 2029. The only possibility of earlier launch is through AA based on early cohorts data when nvg-291 will get conditional approval and final approval will happen after p3 completion.
0 · Reply
Floridaorange
Floridaorange Aug. 13 at 11:12 PM
$NGEN A fascinating key detail for me is the 1–10 years post-injury, mean 3.5 years. Natural-history literature shows that most spontaneous motor recovery after traumatic SCI occurs during the first 6–9 months & generally plateaus by about 12–18 months. CONNECT wasn’t taking ppl 3 months after an accident, when substantial natural recovery could contaminate the result. These people were, on avg, yrs removed from injury.Against that background, the gait analysis found: 10/10 NVG-291 patients met the responder criterion 1/10 placebo patients met it. Responder comparison: p ≈ 0.0001 Overall multivariate gait effect: p = 0.0197 Coordination: p = 0.007 Mechanical effort: p = 0.038 Postural stability: p = 0.044 & there’s an important technical detail: “responder” wasn’t simply “the patient walked a bit better.” $NGEN SEC filing says a responder was someone who outperformed the majority of subjects in the opposite treatment arm across the composite of coordination, effort and stability.
0 · Reply
Floridaorange
Floridaorange Aug. 13 at 8:47 PM
$NGEN encouraging ER 👍
1 · Reply
aladdinscarpet
aladdinscarpet Aug. 13 at 8:25 PM
$NGEN DENIED. No soup for you.
3 · Reply
Westjtter
Westjtter Aug. 13 at 7:54 PM
$NGEN Most fledgling Biotechs are not going to waste a major announcement in August when all of the Big traders are at the Hamptons, or some other dreamy holiday location. I know September can be a dicey month(or has been historically) for the stock market, but a good solid News Release kicking off our ph 3 should give us a decent boost! Till then it is one boring day after another...a good time to pick up shares mind you!
1 · Reply
derekiz
derekiz Aug. 13 at 6:11 PM
0 · Reply
Tarquinjones
Tarquinjones Aug. 13 at 5:14 PM
$NGEN look dad. We’re up a penny. We’re doing it. We’re really doing it.
1 · Reply
Latest News on NGEN
NervGen Pharma Earnings release: Q2 2026

Aug 13, 2026, 9:00 AM EDT - 17 hours ago

NervGen Pharma Earnings release: Q2 2026


NervGen Pharma initiated with an Outperform at Leerink

2026-07-13T11:45:36.000Z - 4 weeks ago

NervGen Pharma initiated with an Outperform at Leerink


NervGen Pharma initiated with a Buy at TD Cowen

2026-06-11T09:51:08.000Z - 2 months ago

NervGen Pharma initiated with a Buy at TD Cowen


NervGen Pharma files $250M mixed securities shelf

2026-05-26T13:28:30.000Z - 2 months ago

NervGen Pharma files $250M mixed securities shelf


NervGen Pharma Registration statement: Registration filing

May 26, 2026, 8:00 AM EDT - 2 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma 24M share Spot Secondary priced at $2.50

2026-05-22T10:31:38.000Z - 2 months ago

NervGen Pharma 24M share Spot Secondary priced at $2.50


NervGen Pharma secondary being re-offered at $2.50 per share

2026-05-21T23:20:11.000Z - 3 months ago

NervGen Pharma secondary being re-offered at $2.50 per share


NervGen Pharma announces common share offering, no amount given

2026-05-21T20:06:04.000Z - 3 months ago

NervGen Pharma announces common share offering, no amount given


NervGen Announces Proposed Public Offering of Securities

May 21, 2026, 4:01 PM EDT - 3 months ago

NervGen Announces Proposed Public Offering of Securities


NervGen Pharma Slides: Corporate presentation

May 21, 2026, 7:00 AM EDT - 3 months ago

NervGen Pharma Slides: Corporate presentation


NervGen Pharma reports Q1 EPS (2c), consensus (7c)

2026-05-18T11:26:55.000Z - 3 months ago

NervGen Pharma reports Q1 EPS (2c), consensus (7c)


NervGen Pharma Earnings release: Q1 2026

May 18, 2026, 7:00 AM EDT - 3 months ago

NervGen Pharma Earnings release: Q1 2026


NervGen Pharma appoints Keith Vendola as CFO

2026-04-27T11:49:46.000Z - 3 months ago

NervGen Pharma appoints Keith Vendola as CFO


NervGen Pharma initiated with a Buy at H.C. Wainwright

2026-04-27T10:13:14.000Z - 3 months ago

NervGen Pharma initiated with a Buy at H.C. Wainwright


NervGen Pharma Transcript: HCW Home with NervGen Conference

Apr 15, 2026, 7:00 AM EDT - 4 months ago

NervGen Pharma Transcript: HCW Home with NervGen Conference


NervGen Pharma initiated with a Buy at Lucid Capital

2026-04-15T10:11:00.000Z - 4 months ago

NervGen Pharma initiated with a Buy at Lucid Capital


NervGen Pharma price target raised to $12 from $10 at Maxim

2026-04-08T19:20:16.000Z - 4 months ago

NervGen Pharma price target raised to $12 from $10 at Maxim


NervGen Pharma Annual report: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 4 months ago

NervGen Pharma Annual report: Q4 2025


NervGen Pharma Earnings release: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 4 months ago

NervGen Pharma Earnings release: Q4 2025


NervGen Pharma to delist shares from TSX

2026-03-12T21:20:54.000Z - 5 months ago

NervGen Pharma to delist shares from TSX


NervGen Pharma price target raised to C$6.75 from C$5 at Stifel

2026-03-05T17:15:53.000Z - 5 months ago

NervGen Pharma price target raised to C$6.75 from C$5 at Stifel


NervGen Pharma to Participate at Upcoming Investor Conferences

Feb 18, 2026, 7:30 AM EST - 6 months ago

NervGen Pharma to Participate at Upcoming Investor Conferences


NervGen Pharma Begins Trading on Nasdaq Today

Jan 8, 2026, 6:30 AM EST - 7 months ago

NervGen Pharma Begins Trading on Nasdaq Today


NervGen Pharma Registration statement: Registration filing

Jan 7, 2026, 7:00 AM EST - 7 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma Registration statement: Registration filing

Dec 17, 2025, 7:00 AM EST - 8 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma Announces Proposed Amendment to Warrants

Dec 12, 2025, 7:51 PM EST - 8 months ago

NervGen Pharma Announces Proposed Amendment to Warrants


NervGen Pharma Earnings release: Q3 2025

Nov 25, 2025, 7:00 AM EST - 9 months ago

NervGen Pharma Earnings release: Q3 2025


NervGen Pharma Earnings release: Q2 2025

Aug 26, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q2 2025


NervGen Pharma Grants Stock Options

May 16, 2025, 4:30 PM EDT - 1 year ago

NervGen Pharma Grants Stock Options


NervGen Pharma Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q1 2025


NervGen Pharma Earnings release: Q4 2024

Apr 3, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q4 2024


NervGen Initiates Expanded Access Policy

Mar 31, 2025, 7:30 AM EDT - 1 year ago

NervGen Initiates Expanded Access Policy


NervGen Pharma to Host Virtual Investor Event

Mar 25, 2025, 8:30 AM EDT - 1 year ago

NervGen Pharma to Host Virtual Investor Event


NervGen Announces "At-The-Market" Equity Program

Dec 20, 2024, 7:30 AM EST - 1 year ago

NervGen Announces "At-The-Market" Equity Program


NervGen Pharma Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

NervGen Pharma Earnings release: Q3 2024


shopno
shopno Aug. 14 at 5:41 AM
$NGEN appreciate the timelines compilation.. This timeline is even slower than my independent projection.. so 2029 H2 is the timeline to get nvg-291 in general regulatory process! My goodness! What a horrible management to take 15+ months from P1/2 topline to P3 initiation — that’s even for a p3 only with target 150 enrollment. Bag holders should be glad stock is not trading in pennies. Dead money for next few quarters. Down only -72% from 52w peak even after gait data.
0 · Reply
Skaped
Skaped Aug. 14 at 3:49 AM
$NGEN Once again a few sneaky changes have been made on the website. 1) Page 31 of presentation has been updated: SEPTEMBER 2026: RESTORE site activation and participant screening FALL 2026: Formal announcement of additional clinical indications for NVG-291 with biological rationale 2H 2027: Completion of enrollment in Phase 3 RESTORE study 1H 2028: Topline Data from Phase 3 RESTORE study 2H 2028: New Drug Application submission to FDA in chronic spinal cord injury 2) NervGen is tossing away the term "Chronic Tetraplegia" and has changed nearly everything to "Chronic Spinal Cord Injury". This is more directly advertising they are aiming for commercialization for all of it. Even their presentation has changed the wording from "Mid-2028 New Drug Application submission to FDA in chronic tetraplegia" to "2H 2028 New Drug Application submission to FDA in chronic spinal cord injury"
0 · Reply
Tarquinjones
Tarquinjones Aug. 14 at 1:45 AM
$NGEN Most meaningful part of today’s release Key secondary endpoints include the Patient and Clinician Global Impression of Change, the Spinal Cord Independence Measure Version III, and the Modified Ashworth Scale for spasticity. A blinded qualitative interview will also assess participants’ lived experience during RESTORE and contextualize clinically meaningful change.
0 · Reply
shopno
shopno Aug. 14 at 12:29 AM
$NGEN As have predicted lately, p3 already got delayed from mid-2026 (Q2) to late Q3. In no world, this incompetent management without any prior experience of launching any blockbuster drug, would keep pushing down p3 completion timeline. I don’t see NGEN can finish p3 enrollment by Q2 2027, so that dosing and data collections could all be done by Q4 2027. We may have a better idea after Q4 earning release, like how many patients got enrolled throughout Q4 quarter. Of course management utterly lacks in professional communication, like how poorly they released the gait analysis data, so they could just mention enrollment ongoing without revealing extract figure . With all that I have limited hope nvg-291 will reach patients before 2029. The only possibility of earlier launch is through AA based on early cohorts data when nvg-291 will get conditional approval and final approval will happen after p3 completion.
0 · Reply
Floridaorange
Floridaorange Aug. 13 at 11:12 PM
$NGEN A fascinating key detail for me is the 1–10 years post-injury, mean 3.5 years. Natural-history literature shows that most spontaneous motor recovery after traumatic SCI occurs during the first 6–9 months & generally plateaus by about 12–18 months. CONNECT wasn’t taking ppl 3 months after an accident, when substantial natural recovery could contaminate the result. These people were, on avg, yrs removed from injury.Against that background, the gait analysis found: 10/10 NVG-291 patients met the responder criterion 1/10 placebo patients met it. Responder comparison: p ≈ 0.0001 Overall multivariate gait effect: p = 0.0197 Coordination: p = 0.007 Mechanical effort: p = 0.038 Postural stability: p = 0.044 & there’s an important technical detail: “responder” wasn’t simply “the patient walked a bit better.” $NGEN SEC filing says a responder was someone who outperformed the majority of subjects in the opposite treatment arm across the composite of coordination, effort and stability.
0 · Reply
Floridaorange
Floridaorange Aug. 13 at 8:47 PM
$NGEN encouraging ER 👍
1 · Reply
aladdinscarpet
aladdinscarpet Aug. 13 at 8:25 PM
$NGEN DENIED. No soup for you.
3 · Reply
Westjtter
Westjtter Aug. 13 at 7:54 PM
$NGEN Most fledgling Biotechs are not going to waste a major announcement in August when all of the Big traders are at the Hamptons, or some other dreamy holiday location. I know September can be a dicey month(or has been historically) for the stock market, but a good solid News Release kicking off our ph 3 should give us a decent boost! Till then it is one boring day after another...a good time to pick up shares mind you!
1 · Reply
derekiz
derekiz Aug. 13 at 6:11 PM
0 · Reply
Tarquinjones
Tarquinjones Aug. 13 at 5:14 PM
$NGEN look dad. We’re up a penny. We’re doing it. We’re really doing it.
1 · Reply
Tarquinjones
Tarquinjones Aug. 13 at 5:00 PM
$NGEN lotta positivity here today. Loving the price action. #mooning
1 · Reply
kenridge
kenridge Aug. 13 at 3:44 PM
$NGEN addressed in the PR: "The event will highlight the biological rationale supporting NVG-291 as a neuroreparative therapeutic candidate, clinical data generated to date, the Phase 3 RESTORE study and the Company’s broader clinical development strategy" Note - "and the company's broader clinical development strategy." An R&D Day is not held in isolation; it is engineered by corporate investor relations to serve as a major valuation catalyst and narrative reset. Management will naturally couple the broad pipeline presentation with the formal unveiling of the next indication framework
1 · Reply
OldManLogan
OldManLogan Aug. 13 at 3:12 PM
$NGEN Abandoning the new indications before they've even started would be like finding $10 billion and deciding to throw it away instead of putting it in the bank. So, I don't imagine they've abandoned anything. However, why not give Huitt a call and ask, I find he's very responsive.
1 · Reply
alexandredaigneault96
alexandredaigneault96 Aug. 13 at 2:16 PM
$NGEN did the company abandon the new indications? No report of them in the update ?
1 · Reply
OldManLogan
OldManLogan Aug. 13 at 12:17 PM
$NGEN Good update, though I do agree with @jerrybe5000 that mgmt needs to start doing quarterly calls to be taken seriously going forward. $87M in the bank, plus access to ATM and warrants $$$ mean no more financing before topping data, which is a huge deal. We probably have something to look forward to each month for the next while...
1 · Reply
OldManLogan
OldManLogan Aug. 13 at 11:42 AM
$NGEN Seems to want the 80s today...
1 · Reply
Skaped
Skaped Aug. 13 at 11:37 AM
$NGEN https://nervgen.com/nervgen-reports-second-quarter-2026-financial-results-and-provides-business-updates/
2 · Reply
Floridaorange
Floridaorange Aug. 13 at 11:34 AM
$NGEN what updates might there be 8 trading days from today during pre-market ER?
0 · Reply
Hrumph63
Hrumph63 Aug. 13 at 1:48 AM
$NGEN Bullish.. very bullish but..
0 · Reply
Westjtter
Westjtter Aug. 12 at 10:19 PM
$NGEN OK, lets look at it another way....we were just under $6 in January, (and are now in a much stronger position)....we have a nice Nasdaq listing, we have competent management in now, who are capable of setting up and administering a ph 3 trial. I would expect an announcement in the not to distant future that the ph 3 design is complete and a OK'd by the FDA for enrollment to commence. We have 82 million shares outstanding with a market float of 64 million....it will take very little for this stock to spike with such a tiny market cap. As mentioned earlier....perhaps some boring trading till then, but I really believe we have a good one here!!!
3 · Reply
Tarquinjones
Tarquinjones Aug. 12 at 8:06 PM
$NGEN we did it. up 2 cents again on 386,000 shares of volume. that's all we need. just another 512 sessions of that to get to LEERINK's Price target. were on the way. Where's that SPARTAN guy? LET'S Fucking go. we're doing it. were really doing it. look dad. 2 cents. up 2 cents.
3 · Reply
Westjtter
Westjtter Aug. 12 at 7:25 PM
$NGEN Very tough to get a big position in this company because of the low volume....I have been buying daily and it takes almost nothing to push the price higher...by nothing I mean buys of 5000 to 10,000. I still believe the base case here is in the $2.60 range(which would free up the buyers of the last financing to dump their shares and hold on to their free options). Just announcing the start of the ph 3 should put us firmly back in the 2.50 range....of course with the right centers participating, you could see a whole lot more upside...even at the start of the ph 3. Of course if the ph 3 is administered properly and we even get close to the efficacy shown in the ph 1/2 trial(really even modest efficacy).....well there will be a lot of happy longs here.....meanwhile it could be some boring trading for a while.
7 · Reply